Venous Thrombosis Clinical Trial
Official title:
Randomized, Placebo-controlled, Parallel-group Study in Healthy Male Subjects to Investigate the Pharmacodynamics During the Switching Procedure From Warfarin to Rivaroxaban
The study objective is to investigate the pharmacodynamics (effects of a drug product) when
switching the treatment from warfarin to rivaroxaban.
84 young, healthy subjects will participate; they will be treated following a randomized,
parallel-group (Treatments A, B, and C), placebo-controlled (Treatment B), and single-blind
(Treatments A and B) design.
The first two groups (A, B) will receive warfarin for approximately one week to adjust their
blood coagulation values to a specific level, i.e. to maintain an INR (international
normalized ratio) of 2.0 - 3.0. This range is commonly used for long-term anticoagulant
treatment.
The first group (A) will receive rivaroxaban for four days, the second group (B) will take
placebo. On the last day, all subjects in groups A and B will receive vitamin K to
neutralize the effects of warfarin. The third group (C) will not undergo prior treatment
with warfarin but will receive rivaroxaban for four days.
n/a
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02567903 -
Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System
|
N/A | |
| Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
| Recruiting |
NCT02650453 -
Ongoing Registry of Deep Venous Reconstructions
|
N/A | |
| Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
| Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
| Terminated |
NCT00872079 -
Personalized Warfarin Dosing by Genomics and Computational Intelligence
|
N/A | |
| Terminated |
NCT00521885 -
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
|
N/A | |
| Completed |
NCT02892565 -
Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)
|
N/A | |
| Completed |
NCT00346424 -
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
|
Phase 3 | |
| Active, not recruiting |
NCT04349189 -
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
|
||
| Recruiting |
NCT02238444 -
Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy
|
Phase 4 | |
| Recruiting |
NCT02597218 -
Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.
|
||
| Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
| Completed |
NCT00246025 -
A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.
|
Phase 2 | |
| Completed |
NCT00097357 -
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
|
Phase 2/Phase 3 | |
| Completed |
NCT04645550 -
Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）
|
Phase 4 | |
| Recruiting |
NCT02264743 -
Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy
|
Phase 4 | |
| Completed |
NCT01482273 -
Ultrasound-enhanced Thrombolysis Versus Standard Catheter Directed Thrombolysis for Ilio-femoral Deep Vein Thrombosis
|
N/A | |
| Recruiting |
NCT01252420 -
Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis
|
Phase 4 | |
| Completed |
NCT01145859 -
Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects
|
Phase 1 |